These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties, and intracellular distribution. Vogel V; Lochmann D; Weyermann J; Mayer G; Tziatzios C; van den Broek JA; Haase W; Wouters D; Schubert US; Kreuter J; Zimmer A; Schubert D J Control Release; 2005 Mar; 103(1):99-111. PubMed ID: 15710504 [TBL] [Abstract][Full Text] [Related]
3. Comparison of antisense oligonucleotide drug delivery systems. Weyermann J; Lochmann D; Zimmer A J Control Release; 2004 Dec; 100(3):411-23. PubMed ID: 15567506 [TBL] [Abstract][Full Text] [Related]
4. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect. Weyermann J; Lochmann D; Georgens C; Zimmer A Eur J Pharm Biopharm; 2005 Apr; 59(3):431-8. PubMed ID: 15760723 [TBL] [Abstract][Full Text] [Related]
5. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles. Wernig K; Griesbacher M; Andreae F; Hajos F; Wagner J; Mosgoeller W; Zimmer A J Control Release; 2008 Sep; 130(2):192-8. PubMed ID: 18601963 [TBL] [Abstract][Full Text] [Related]
6. Fluorescence correlation spectroscopy for the characterisation of drug delivery systems. Delie F; Gurny R; Zimmer A Biol Chem; 2001 Mar; 382(3):487-90. PubMed ID: 11347898 [TBL] [Abstract][Full Text] [Related]
7. Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration. Scheicher B; Lorenzer C; Gegenbauer K; Partlic J; Andreae F; Kirsch AH; Rosenkranz AR; Werzer O; Zimmer A PLoS One; 2016; 11(11):e0164149. PubMed ID: 27828968 [TBL] [Abstract][Full Text] [Related]
8. Ternary nanoparticles of anionic lipid nanoparticles/protamine/DNA for gene delivery. Yuan H; Zhang W; Du YZ; Hu FQ Int J Pharm; 2010 Jun; 392(1-2):224-31. PubMed ID: 20230883 [TBL] [Abstract][Full Text] [Related]
9. Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization. Lochmann D; Weyermann J; Georgens C; Prassl R; Zimmer A Eur J Pharm Biopharm; 2005 Apr; 59(3):419-29. PubMed ID: 15760722 [TBL] [Abstract][Full Text] [Related]
10. Uptake of oleoyl-chitosan nanoparticles by A549 cells. Zhang J; Chen XG; Peng WB; Liu CS Nanomedicine; 2008 Sep; 4(3):208-14. PubMed ID: 18508414 [TBL] [Abstract][Full Text] [Related]
11. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762 [TBL] [Abstract][Full Text] [Related]
12. Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. Zhang L; Hou S; Mao S; Wei D; Song X; Lu Y Int J Pharm; 2004 Dec; 287(1-2):155-62. PubMed ID: 15541922 [TBL] [Abstract][Full Text] [Related]
13. N-acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: endocytosis, exocytosis and drug release. Park JS; Han TH; Lee KY; Han SS; Hwang JJ; Moon DH; Kim SY; Cho YW J Control Release; 2006 Sep; 115(1):37-45. PubMed ID: 16935380 [TBL] [Abstract][Full Text] [Related]
14. Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation. Dinauer N; Lochmann D; Demirhan I; Bouazzaoui A; Zimmer A; Chandra A; Kreuter J; von Briesen H J Control Release; 2004 May; 96(3):497-507. PubMed ID: 15120905 [TBL] [Abstract][Full Text] [Related]
15. Analysis of the complex formation of heparin with protamine by light scattering and analytical ultracentrifugation: implications for blood coagulation management. Maurer J; Haselbach S; Klein O; Baykut D; Vogel V; Mäntele W J Am Chem Soc; 2011 Feb; 133(4):1134-40. PubMed ID: 21186806 [TBL] [Abstract][Full Text] [Related]